- Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
- Chen H, Liu Y, Yin Z, Chen H, Wang Y, Qian Y.
- Cell Cycle. 2023 Feb 9:1-24. doi: 10.1080/15384101.2023.2174339. Epub ahead of print.
- PMID: 36757135
- PubMed abstract
- Source abstract
- Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
- Huang Y, Liu C, You L, Li X, Chen G, Fan J.
- J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.
- PMID: 36753396
- PubMed abstract
- Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC.
- Choudhury AD.
- OncLive. OncLive TV. 2023 Feb 8.
- Review
- Free Video
- Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2.
- Rao ND, Shirts BH.
- PLoS One. 2023 Feb 8;18(2):e0278010. doi: 10.1371/journal.pone.0278010.
- PMID: 36753473
- PubMed abstract
- Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL.
- JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- PMID: 36753688
- PubMed abstract
- Source abstract
•• Identifier: NCT02693535: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR). (ClinicalTrials.gov . Accessed 2023 Feb 8.)
- BRCA1/2 pathogenic variants are not common in Merkel cell carcinoma: Comprehensive molecular study of 30 cases and meta-analysis of the literature.
- Gaubert A, Kervarrec T, Montaudié H, Burel-Vandenbos F, Cardot-Leccia N, Di Mauro I, Fabas T, Tallet A, Kubiniek V, Pedeutour F, Dadone-Montaudié B.
- J Invest Dermatol. 2023 Feb 6:S0022-202X(23)00068-4. doi: 10.1016/j.jid.2023.01.014. Epub ahead of print.
- PMID: 36754117
- PubMed abstract
- Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
- Zheng J, Li Z, Min W.
- Front Pharmacol. 2023 Jan 23;13:979873. doi: 10.3389/fphar.2022.979873.
- PMID: 36756144
- PubMed abstract
- Review
- Free PMC article
- Free Full Text
- Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.
- Yu L, Lin J, Li H, Sun L, Wang S, Chen Y, Chen H, Lin L.
- Front Pharmacol. 2023 Jan 23;14:997760. doi: 10.3389/fphar.2023.997760.
- PMID: 36755949
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text